Consider the most successful drug launches of the past few years. The Covid vaccines, of course. But more interesting: the unexpected success of Tepezza, from Horizon, which is being acquired by Amgen.
read full article ›The guest essay in the New York Times from Fyodor Urnov is an important reality check about how far we have come - and how far we still need to go - to make innovations like gene editing a reality.
read full article ›ALS patients reacted to excitement when the first drug to slow disease progression and functional decline was approved earlier this year. But as this article reminds, despite the fact that the ALS community has worked diligently to change the Medicare policy, a coverage gap still exists.
read full article ›In lieu of gifts this holiday season, Real Endpoints has donated to the American Cancer Society in recognition of the life-changing advances our clients bring to market.
read full article ›The team at Real Endpoints took a quick break from advising clients to prognosticate on all things market access in 2023 and here are the results.
read full article ›Real Endpoints CEO Jeff Berkowitz is looking forward to connecting with clients and old friends to talk top trends and what's ahead in the realm of drug pricing and market access in 2023. To connect with Jeff, reach out through LinkedIn or send an email to info@realendpoints.com
read full article ›So many insights in this piece that resonate with our own thought leadership. The inflation reduction act adds important new wrinkles to a product pricing strategy that companies need to address much earlier in the development cycle than they traditionally do.
read full article ›Eisa's press release on its pricing decision for Leqembi (lecanemab) is worth studying for so many reasons. From a communications perspective, this is a great example of how to get in front of what is sure to be a controversial topic - system affordability - and own the narrative.
read full article ›